• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Puerto Rico Pharmaceuticals and Healthcare Report Q3 2008 - Product Image

Puerto Rico Pharmaceuticals and Healthcare Report Q3 2008

  • Published: September 2008
  • Region: Puerto Rico
  • 57 Pages
  • Business Monitor International


  • Abbott Laboratories
  • Eli Lilly
  • GlaxoSmithKline
  • Merck & Co
  • Pfizer
  • MORE

Puerto Rico Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Puerto Rico's pharmaceuticals and healthcare industry.

Puerto Rico’s ongoing economic problems will impact the pharmaceutical market over the forecast period. According, to BMI’s drug sector calculations, -based on our new industry modelling system, the total market will reach a value of US$4,139.3mn by 2012, up from US$2,647mn in 2007. In 2008, the nominal growth rate of the market will be 9.9%. However, in real terms, growth will be in negative territory, showing the inflationary pressure bearing on the market.

In terms of company activity, the latest quarter has been quiet. One interesting move has been the return of Israeli generics firm Teva to manufacturing on the Island, after purchasing an API plant from Germany’s Archimica. On a less positive note, Canadian drugmaker Biovail is to close two of its manufacturing plants in Puerto Rico, as it seeks to restructure following disappointing financial results. Production will transfer to the company's existing facility in Steinbach, Manitoba. The closures are expected to take between18 months READ MORE >

Executive Summary
Puerto Rico Pharmaceuticals And Healthcare Industry SWOT
Business Environment Rating
Puerto Rico – Business Environment Rating
Table: Americas Pharmaceutical Business Environment Ratings
Limits To Potential Returns
Puerto Rico – Market Summary
Regulatory Regime
Pricing And Reimbursement Issues
Tax Incentives
Table: Puerto Rico – Incentives, Benefits And Discounts For Pharmaceutical Manufacturers
Trade Accords
Industry Developments
Company Activity
Industry Forecast Scenario
Overall Market Forecast
Table: Drug Market Forecasts
Macroeconomic Forecast
Table: Puerto Rico: Historical Data And Forecasts
Patented Market Forecast
Table: Prescription Market Forecasts, 2006-2012 (US$mn unless otherwise stated)
Table: OTC Market Forecasts, 2005-2012 (US$mn unless otherwise stated)
Generics Market Forecast
Table: Generics Market Forecasts, 2005-2012
Medical Device Market Forecast
Table: Puerto Rico Medical Device Market Forecast
Export/Import Forecasts
Table: Puerto Rico’s Pharmaceuticals Exports And Imports, 2005-2012 (US$mn)
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Table: Pharmaceutical Sales In Puerto Rico (US$mn), August 2007, MAT
Company Monitor
Eli Lilly
Abbott Laboratories
Merck & Co
Regional Overview – Central America And Caribbean, DR-CAFTA Region
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Table: Weighting Of Components

- Eli Lilly
- Abbott Laboratories
- Pfizer
- GlaxoSmithKline
- Merck & Co

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos